Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model

Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharpe, Ashley N., Oldach, Maureen S., Kaplan, Joanna L., Rivas, Victor, Kovacs, Samantha L., Hwee, Darren T., Morgan, Bradley P., Malik, Fady I., Harris, Samantha P., Stern, Joshua A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099566/
https://www.ncbi.nlm.nih.gov/pubmed/36382714
http://dx.doi.org/10.1111/jvp.13103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099566/
https://www.ncbi.nlm.nih.gov/pubmed/36382714
http://dx.doi.org/10.1111/jvp.13103

Ejemplares similares